Marie Hjälm-Eriksson

Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA

Stéphane Oudard, Karim Fizazi, Lisa Sengeløv et al. · Journal of Clinical Oncology · 2017 · 350 citations

The updated ESTRO core curricula 2011 for clinicians, medical physicists and RTTs in radiotherapy/radiation oncology

Jesper Grau Eriksen, Andrew Beavis, Mary Coffey et al. · Radiotherapy and Oncology · 2012 · 88 citations · Full text

Capture rate and representativity of The National Prostate Cancer Register of Sweden

Katarina Tomić, Anders Berglund, David Robinson et al. · Acta Oncologica · 2014 · 82 citations · Full text

An expression signature at diagnosis to estimate prostate cancer patients’ overall survival

Zheng Peng, Lambert Skoog, Henrik Hellborg et al. · Prostate Cancer and Prostatic Diseases · 2014 · 44 citations · Full text

Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer—Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial

Pirkko‐Liisa Kellokumpu‐Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg‐Karlsson et al. · European Urology · 2019 · 33 citations

High-risk Prostate Cancer—results, Urology, Radiation Medicine +7